DESTINY-Breast04 and Other Key Breast Cancer Studies at ASCO22

DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancerПодробнее

Harold Burstein, MD, PhD on advances in breast cancer research from ASCO 2022Подробнее

DESTINY-Breast04: practice-changing results for HER2-low breast cancerПодробнее

ASCO 2022: DESTINY-Breast04, PALOMA-2, rEECurПодробнее

Key takeaways from ASCO 2022Подробнее

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsПодробнее

ASCO22 Metastatic Breast Cancer Updates | Lee Schwartzberg, MD | Renown Institute for CancerПодробнее

What to look forward to in breast cancer at ASCO 2022?Подробнее

ASCO2022 DESTINY BREAST 04 - How can we interpret a trial without pre or post treatment information?Подробнее

DESTINY-Breast04: T-DXd for patients with HER2-low mBCПодробнее

DESTINY-Breast04 Study Discussion - OncBrothers (Rohit and Rahul Gosain) with Dr. Shanu ModiПодробнее

Reflections on the DESTINY-Breast04 trial | Patricia LoRussoПодробнее

DESTINY-04: HER2 1+/FISH- Metastatic Breast Cancer TDXD Treatment | Jane Meisel, MD | ASCO22 UpdatesПодробнее

Behind the Breakthroughs: Groundbreaking Results at ASCO 2022Подробнее

DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBCПодробнее

Breast cancer highlights at ASCO 2022Подробнее

Breast cancer highlights from the 2022 ASCO Annual Meeting | Harold BursteinПодробнее

ASCO22: Breast cancer research by Sara Tolaney, MD | Dana-Farber Cancer InstituteПодробнее